La Jolla Pharmaceutical (NASDAQ:LJPC) has been assigned a consensus recommendation of “Hold” from the ten analysts that are covering the company, MarketBeat Ratings reports. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $66.40.
A number of equities analysts have recently weighed in on LJPC shares. ValuEngine cut shares of La Jolla Pharmaceutical from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. JPMorgan Chase & Co. cut shares of La Jolla Pharmaceutical from an “overweight” rating to an “underweight” rating and set a $20.00 price target on the stock. in a research report on Friday, December 8th. BidaskClub cut shares of La Jolla Pharmaceutical from a “sell” rating to a “strong sell” rating in a research report on Friday, December 15th. HC Wainwright assumed coverage on shares of La Jolla Pharmaceutical in a research report on Thursday, December 21st. They set a “buy” rating and a $62.00 price target on the stock. Finally, SunTrust Banks restated a “buy” rating and set a $65.00 price objective (down from $67.00) on shares of La Jolla Pharmaceutical in a report on Friday, December 22nd.
In other La Jolla Pharmaceutical news, Director Kevin C. Tang purchased 508,474 shares of the stock in a transaction on Thursday, March 15th. The shares were purchased at an average cost of $29.50 per share, for a total transaction of $14,999,983.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, COO Jennifer Carver purchased 1,000 shares of the stock in a transaction on Wednesday, December 27th. The stock was acquired at an average price of $33.22 per share, for a total transaction of $33,220.00. Following the completion of the purchase, the chief operating officer now directly owns 4,500 shares in the company, valued at approximately $149,490. The disclosure for this purchase can be found here. Over the last 90 days, insiders have purchased 846,474 shares of company stock worth $25,902,303. 25.47% of the stock is currently owned by company insiders.
Shares of LJPC stock traded down $0.20 during midday trading on Wednesday, hitting $28.45. 310,309 shares of the stock were exchanged, compared to its average volume of 713,606. The company has a market capitalization of $747.12, a PE ratio of -5.27 and a beta of 1.30. La Jolla Pharmaceutical has a 52 week low of $22.68 and a 52 week high of $41.36.
La Jolla Pharmaceutical (NASDAQ:LJPC) last announced its quarterly earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($1.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.25) by ($0.49). research analysts expect that La Jolla Pharmaceutical will post -5 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “La Jolla Pharmaceutical (LJPC) Receives $68.00 Average PT from Analysts” was reported by Ticker Report and is the property of of Ticker Report. If you are accessing this story on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The legal version of this story can be accessed at https://www.tickerreport.com/banking-finance/3296421/la-jolla-pharmaceutical-ljpc-receives-68-00-average-pt-from-analysts.html.
La Jolla Pharmaceutical Company Profile
La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH).
Receive News & Ratings for La Jolla Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.